Home > Publications database > The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases. > print

001     289472
005     20250820103547.0
024 7 _ |a 10.1016/j.medj.2024.03.016
|2 doi
024 7 _ |a pmid:38608709
|2 pmid
024 7 _ |a 2666-6340
|2 ISSN
024 7 _ |a 2666-6359
|2 ISSN
024 7 _ |a altmetric:162307533
|2 altmetric
037 _ _ |a DKFZ-2024-00794
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Shu, Jinhui
|b 0
245 _ _ |a The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases.
260 _ _ |a Amsterdam
|c 2024
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1718698283_17667
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2024 Jun 14;5(6):495-529
520 _ _ |a Chimeric antigen receptor (CAR) T cells have made a groundbreaking advancement in personalized immunotherapy and achieved widespread success in hematological malignancies. As CAR technology continues to evolve, numerous studies have unveiled its potential far beyond the realm of oncology. This review focuses on the current applications of CAR-based cellular platforms in non-neoplastic indications, such as autoimmune, infectious, fibrotic, and cellular senescence-associated diseases. Furthermore, we delve into the utilization of CARs in non-T cell populations such as natural killer (NK) cells and macrophages, highlighting their therapeutic potential in non-neoplastic conditions and offering the potential for targeted, personalized therapies to improve patient outcomes and enhanced quality of life.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a CAR
|2 Other
650 _ 7 |a CAR macrophage
|2 Other
650 _ 7 |a CAR-NK
|2 Other
650 _ 7 |a autoimmune diseases
|2 Other
650 _ 7 |a cellular senescence
|2 Other
650 _ 7 |a fibrotic diseases
|2 Other
650 _ 7 |a infectious diseases
|2 Other
700 1 _ |a Xie, Wei
|b 1
700 1 _ |a Chen, Zhaozhao
|b 2
700 1 _ |a Offringa, Rienk
|0 P:(DE-He78)81ae96953d6149e4307057d71a190019
|b 3
|u dkfz
700 1 _ |a Hu, Yu
|b 4
700 1 _ |a Mei, Heng
|b 5
773 _ _ |a 10.1016/j.medj.2024.03.016
|g p. S2666634024001284
|0 PERI:(DE-600)3050845-9
|n 6
|p 495-529
|t Med
|v 5
|y 2024
|x 2666-6340
856 4 _ |u https://inrepo02.dkfz.de/record/289472/files/1-s2.0-S2666634024001284-main.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/289472/files/1-s2.0-S2666634024001284-main.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:289472
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)81ae96953d6149e4307057d71a190019
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MED-CAMBRIDGE : 2022
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-27
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b MED-CAMBRIDGE : 2022
|d 2023-10-27
920 1 _ |0 I:(DE-He78)D200-20160331
|k D200
|l Molekulare Grundlagen Gastrointestinaler Tumoren
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D200-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21